SV2018005776A - Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida - Google Patents

Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida

Info

Publication number
SV2018005776A
SV2018005776A SV2018005776A SV2018005776A SV2018005776A SV 2018005776 A SV2018005776 A SV 2018005776A SV 2018005776 A SV2018005776 A SV 2018005776A SV 2018005776 A SV2018005776 A SV 2018005776A SV 2018005776 A SV2018005776 A SV 2018005776A
Authority
SV
El Salvador
Prior art keywords
trifluorometil
methylbuty
piridin
indazol
carboxamide
Prior art date
Application number
SV2018005776A
Other languages
English (en)
Inventor
Tobias Thaler
Johannes Platzek
Nicolas Guimond
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2018005776A publication Critical patent/SV2018005776A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A LAS FORMAS DE N-[2-(3-HIDROXI-3-METILBUTIL)-6-(2- HIDROXIPROPAN-2-IL)-2H-INDAZOL-5-IL]-6-(TRIFLUOROMETIL)PIRIDIN-2-CARBOXAMIDA, A LOS PROCESOS PARA SU PREPARACIÓN, A LAS COMPOSICIONES FARMACÉUTICAS QUE LAS COMPRENDEN Y A SU USO EN EL CONTROL DE TRASTORNOS
SV2018005776A 2016-04-29 2018-10-29 Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida SV2018005776A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16167649 2016-04-29
EP16167650 2016-04-29

Publications (1)

Publication Number Publication Date
SV2018005776A true SV2018005776A (es) 2019-03-18

Family

ID=58579196

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005776A SV2018005776A (es) 2016-04-29 2018-10-29 Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida

Country Status (37)

Country Link
US (2) US10501437B2 (es)
EP (2) EP3448847A1 (es)
JP (2) JP6821701B2 (es)
KR (2) KR102409105B1 (es)
CN (4) CN118184628A (es)
AU (2) AU2017256659B2 (es)
BR (1) BR112018072247A2 (es)
CA (2) CA3022329A1 (es)
CL (2) CL2018003085A1 (es)
CO (2) CO2018011655A2 (es)
CU (1) CU24593B1 (es)
DK (1) DK3448849T3 (es)
DO (1) DOP2018000236A (es)
EA (1) EA038103B1 (es)
EC (1) ECSP18081451A (es)
ES (1) ES2801800T3 (es)
GE (1) GEP20217230B (es)
HU (1) HUE049331T2 (es)
IL (2) IL262391B (es)
JO (2) JOP20170101B1 (es)
LT (1) LT3448849T (es)
MA (1) MA44758A (es)
MX (2) MX2018013232A (es)
NI (1) NI201800111A (es)
PE (2) PE20190172A1 (es)
PH (1) PH12018502288A1 (es)
PL (1) PL3448849T3 (es)
PT (1) PT3448849T (es)
RS (1) RS60419B1 (es)
SG (2) SG11201808686VA (es)
SI (1) SI3448849T1 (es)
SV (1) SV2018005776A (es)
TN (1) TN2018000359A1 (es)
TW (3) TW201936599A (es)
UA (2) UA122882C2 (es)
UY (2) UY37214A (es)
WO (2) WO2017186700A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
KR102373220B1 (ko) 2016-04-29 2022-03-11 바이엘 파마 악티엔게젤샤프트 인다졸의 합성
GEP20217230B (en) 2016-04-29 2021-03-10 Bayer Pharma AG Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
RU2743170C2 (ru) * 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
EP3816164B9 (en) 2018-06-25 2024-07-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Isothiazolo[5,4-d]pyrimidine compound as irak4 inhibitor
KR102392788B1 (ko) 2019-01-08 2022-04-28 주식회사 엘지에너지솔루션 폴더블 사이드 플레이트를 구비하는 배터리 모듈 및 그 제조 방법
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
AU2007213452A1 (en) 2006-02-10 2007-08-16 Biomarin Iga Limited Treatment of Duchenne muscular dystrophy
US7879887B2 (en) 2006-06-29 2011-02-01 Nissan Chemical Industries, Ltd. α-amino acid derivatives and medicaments containing the same as an active ingredient
MX2009002377A (es) 2006-09-07 2009-03-13 Biogen Idec Inc Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
US20120196824A1 (en) 2009-10-09 2012-08-02 Mitsubishi Tanabe Pharma Corporation Therapeutic agent for cerebral infarction
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
PL2655357T3 (pl) 2010-12-20 2016-12-30 Pochodne triazolowe indazolilowe jako inhibitory irak
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
WO2014086712A1 (en) * 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
US9126984B2 (en) * 2013-11-08 2015-09-08 Iteos Therapeutics 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10160753B2 (en) * 2014-01-10 2018-12-25 Aurigene Discovery Technologies Limited Indazole compounds as IRAK4 inhibitors
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
CU20180006A7 (es) 2015-07-15 2018-06-05 Aurigene Discovery Tech Ltd Compuestos de indazaol y azaindazol como inhibidores de irak-4
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
KR102373220B1 (ko) 2016-04-29 2022-03-11 바이엘 파마 악티엔게젤샤프트 인다졸의 합성
GEP20217230B (en) 2016-04-29 2021-03-10 Bayer Pharma AG Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
RU2743170C2 (ru) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных

Also Published As

Publication number Publication date
JP6821701B2 (ja) 2021-01-27
MA44758A (fr) 2019-03-06
TWI671291B (zh) 2019-09-11
BR112018072213A2 (pt) 2019-02-12
CO2018011607A2 (es) 2018-11-22
US20190152944A1 (en) 2019-05-23
TWI651316B (zh) 2019-02-21
TW201738231A (zh) 2017-11-01
IL262391B (en) 2022-03-01
ES2801800T3 (es) 2021-01-13
AU2017257208B2 (en) 2022-01-20
ECSP18081451A (es) 2018-11-30
WO2017186693A1 (en) 2017-11-02
JP6916207B2 (ja) 2021-08-11
CA3022329A1 (en) 2017-11-02
AU2017256659A1 (en) 2018-10-25
KR102379948B1 (ko) 2022-03-31
TN2018000359A1 (en) 2020-06-15
HUE049331T2 (hu) 2020-09-28
US10501437B2 (en) 2019-12-10
CN109071491A (zh) 2018-12-21
SI3448849T1 (sl) 2020-07-31
IL262391A (en) 2018-12-31
PE20240651A1 (es) 2024-04-04
CU24593B1 (es) 2022-05-11
WO2017186700A1 (en) 2017-11-02
KR20190002468A (ko) 2019-01-08
CL2018003085A1 (es) 2019-02-15
AU2017257208A1 (en) 2018-11-01
EP3448849B1 (en) 2020-05-13
AU2017256659B2 (en) 2021-05-27
UY37214A (es) 2017-11-30
RS60419B1 (sr) 2020-07-31
PH12018502288A1 (en) 2019-07-15
CO2018011655A2 (es) 2018-11-13
CL2018003097A1 (es) 2019-02-15
JOP20170102B1 (ar) 2023-09-17
TW201936599A (zh) 2019-09-16
EA038103B1 (ru) 2021-07-06
CN109415339A (zh) 2019-03-01
BR112018072247A2 (pt) 2019-02-12
CU20180130A7 (es) 2019-06-04
PE20190172A1 (es) 2019-02-01
US10633365B2 (en) 2020-04-28
EP3448849A1 (en) 2019-03-06
EP3448847A1 (en) 2019-03-06
DOP2018000236A (es) 2019-01-15
MX2018013227A (es) 2019-02-13
US20190144420A1 (en) 2019-05-16
PL3448849T3 (pl) 2020-12-14
JP2019514924A (ja) 2019-06-06
CN109071491B (zh) 2020-08-21
SG11201809172WA (en) 2018-11-29
MX2018013232A (es) 2019-02-13
NI201800111A (es) 2019-08-29
IL262413A (en) 2018-12-31
IL262413B (en) 2021-05-31
UA123550C2 (uk) 2021-04-21
KR20180137498A (ko) 2018-12-27
JOP20170101B1 (ar) 2022-03-14
KR102409105B1 (ko) 2022-06-16
GEP20217230B (en) 2021-03-10
UA122882C2 (uk) 2021-01-13
EA201892407A1 (ru) 2019-05-31
JP2019514921A (ja) 2019-06-06
CA3022327A1 (en) 2017-11-02
DK3448849T3 (da) 2020-06-29
CN112898269A (zh) 2021-06-04
SG11201808686VA (en) 2018-11-29
TW201738233A (zh) 2017-11-01
UY37217A (es) 2017-11-30
LT3448849T (lt) 2020-09-25
PT3448849T (pt) 2020-06-30
CN118184628A (zh) 2024-06-14

Similar Documents

Publication Publication Date Title
SV2018005776A (es) Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipropan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxamida
SV2018005775A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6-(trifluorometil)piridin-2- carboxamida
DOP2019000040A (es) Compuestos de pirrolizina sustituidas y usos de los mismos
SV2018005610A (es) Derivados de oxopiridina sustituidos
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2018000687A1 (es) Nuevos compuestos bicíclicos como inhibidores de atx.
DOP2017000101A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
CL2018000819A1 (es) Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso
ECSP16093323A (es) N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
CO2017007249A2 (es) Modificación cristalina de propanil
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
UY35746A (es) Derivados de fenilalanina sustituidos
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2021000930A1 (es) Piridazinas novedosas
CR20160494A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
CL2019000027A1 (es) Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes.
UY36434A (es) Nuevas formas cristalinas de la sal de monosodio del foramsulfurón